Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus rivoceranib versus sorafenib in first-line advanced hepatocellular carcinoma
2019-000220-18Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Camrelizumab plus rivoceranib with Sorafenib (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started Nov 2019; status: completed.
02
Drugs
camrelizumabRivoceranibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-000220-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000220-18.